| Candidates | Preclinical | Phase 1 | Phase 2 | Phase 3 | reg. filiing | marketed | |
|---|---|---|---|---|---|---|---|
| Tivozanib (RCC) VEGFR 123 TKI |
TIVO - 1 | ||||||
| TIVO - 3 | |||||||
| TiNivo | |||||||
| Tivozanib (HCC) |
DEDUCTIVE | ||||||
| Ficlatuzumab HGF MAb |
SCCHN | ||||||
| Pancreatic | |||||||
| CyFi-2 | |||||||
| AV-203 (CAN017) ERBB3 MAb |
Esophageal | ||||||
| Tivozanib VEGFR 123 TKI |
Non-Oncology | ||||||
| AV-380 GDF15 MAb |
Cachexia | ||||||
| AV-353 Notch 3 MAb |
Oncology | ||||||
| ongoing or complete | in planning | ||||||
| Tivozanib (RCC) VEGFR 123 TKI |
||
| TIVO - 1 | marketed | |
| TIVO - 3 | Phase 3 | |
| TiNivo | Phase 2 | |
| Tivozanib (HCC) |
||
| DEDUCTIVE | Phase 2 | |
| Ficlatuzumab HGF MAb |
||
| SCCHN | Phase 2 | |
| Pancreatic | Phase 2 | |
| CyFi-2 | Phase 2 | |
| AV-203 (CAN017) ERBB3 MAb |
||
| Esophageal | Preclinical | |
| Tivozanib VEGFR 123 TKI |
||
| Non-Oncology | Preclinical | |
| AV-380 GDF15 MAb |
||
| Cachexia | Preclinical | |
| AV-353 Notch 3 MAb |
||
| Oncology | Preclinical | |
AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is seeking to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers. Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks to leverage partnerships to develop and commercialize its pipeline of products and product candidates, including tivozanib in oncology and other indications in various geographies, and ficlatuzumab (HGF MAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates being developed for various oncology indications.
